RT Journal Article
SR Electronic
T1 An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.19.20038984
DO 10.1101/2020.03.19.20038984
A1 Yueping Li
A1 Zhiwei Xie
A1 Weiyin Lin
A1 Weiping Cai
A1 Chunyan Wen
A1 Yujuan Guan
A1 Xiaoneng Mo
A1 Jian Wang
A1 Yaping Wang
A1 Ping Peng
A1 Xudan Chen
A1 Wenxin Hong
A1 Guangming Xiao
A1 Jinxin Liu
A1 Lieguang Zhang
A1 Fengyu Hu
A1 Feng Li
A1 Fuchun Zhang
A1 Xilong Deng
A1 Linghua Li
YR 2020
UL http://medrxiv.org/content/early/2020/03/23/2020.03.19.20038984.abstract
AB Background The novel coronavirus pneumonia (COVID-19) outbreak has caused a global pandemic, however, effective antiviral therapeutics are still unavailable.Methods Our study (NCT04252885), designated as ELACOI, was an exploratory randomized (2:2:1) and controlled one, exploring the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy treating mild/moderate COVID-19 patients.Results This study successful enrolled 44 patients with mild/moderate COVID-19, with 21 randomly assigned to receive LPV/r, 16 to arbidol and 7 to no antiviral medication as control. Baseline characteristics of three groups were comparable. The median time of positive-to-negative conversion of SARS-CoV-2 nucleic acid was 8.5 (IQR 3, 13) days in the LPV/r group, 7 (IQR 3, 10.5) days in the arbidol group and 4 (IQR 3, 10.5) days in the control group (P=0.751). The positive-to-negative conversion rates of SARS-CoV-2 nucleic acid at day 7 and 14 did not show significant differences in the LPV/r group (42.9%, 76.2%), the arbidol group (62.5%, 87.5%) and the control group (71.4%, 71.4%) (all P>0.53). No statistical differences were found among three groups in the rates of antipyresis, cough alleviation, improvement of chest CT or the deterioration rate of clinical status (all P > 0.05). Overall, 5 (23.8%) patients in the LPV/r group experienced adverse events during the follow-up period. No apparent adverse events occurred in the arbidol or control group.Conclusion LPV/r or arbidol monotherapy seems little benefit for improving the clinical outcome of mild/moderate COVID-19. LPV/r might lead to more adverse events. Due to the limitation of small sample size, further verification is needed in the future.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04252885Funding StatementThis study was supported by Chinese 13th Five-Year National Science and technology major project（2018ZX10302103-002, 2017ZX10202102-003-004）, and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in this study are available upon request by contact with the corresponding author.